HIV prevention pill study for people who use drugs
Part of Infections clinical trials.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are HIV-negative (confirmed by a test)
- You have used injection drugs in the last 6 months, or other drugs in the last year
- You can provide a contact person (name and phone number) for follow-up
- Your kidneys are working well enough (creatinine clearance is not too low)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study tests different ways to help people who inject drugs stay on PrEP, a daily pill that prevents HIV. It's for people who are HIV-negative and have recently injected drugs.
This trial tests if daily PrEP medication can help prevent HIV in people receiving opioid replacement therapy. You must be HIV-negative and regularly attend your opioid treatment program to join.
Hear when a new PrEP Adherence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.